Jane E Dematte D'Amico

Grants

Grants per year 2002 2004 2005 2007 2008 2009 2011 2017 2025

• 8 Active
• 32 Finished

Grants per year

Search results

• Active

  Molecular Biomarkers To Guide Therapy In The Systemic Sclerosis-Associated Interstitial Lung Disease

  Misharin, A. & Dematte D'Amico, J. E.

  AbbVie Inc.

  10/19/22 → 10/18/25

  Project: Research project

• Prot #RIN-PF-301: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis

  Dematte D'Amico, J. E.

  United Therapeutics Corporation

  4/28/22 → 4/28/25

  Project: Research project

• Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype Prospective Outcomes (ILD-PRO) Registry

  Dematte D'Amico, J. E.

  Duke University, Boehringer Ingelheim Pharmaceuticals, Inc.

  8/21/20 → 8/21/24

  Project: Research project

• Prot #FGCL-3019-091: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)

  Dematte D'Amico, J. E.

  Worldwide Clinical Trials, Inc., FibroGen, Inc.

  9/9/19 → 7/16/23

  Project: Research project

• Prot #1199.225: An Open-Label Extension Trial to Assess the Long Term Safety of Nintedanib in Patients with 'Systemic Sclerosis Associated Interstitial Lung Disease' (SSc-ILD)

  Dematte D'Amico, J. E.

  Boehringer Ingelheim Pharmaceuticals, Inc.

  5/24/18 → 5/24/23

  Project: Research project

• Prot #ML30172: Scleroderma Lung Study III (SLS III): Combining the anti‐fibrotic effects of pirfenidone (PFD) with mycophenolate (MMF) for treating scleroderma-related interstitial lung disease

  Dematte D'Amico, J. E.

  University of California at Los Angeles, Genentech, Inc.

  1/24/18 → 1/24/24

  Project: Research project

• Prot #IIS2017-10679: Identifying Unique Pathogenic Macrophages in Systemic Sclerosis-ILD using High Throughput Single-cell RNA-Seq

  Gottardi, C., Bhorade, S. M., Dematte D'Amico, J. E., Hinchcliff, M. E. & Lam, A. P.

  Boehringer Ingelheim Pharmaceuticals, Inc.

  12/28/17 → 12/28/23

  Project: Research project

• Prot #1199.247: A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nintedanib over 52 weeks in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

  Dematte D'Amico, J. E.

  Boehringer Ingelheim Pharmaceuticals, Inc.

  8/16/17 → 2/16/24

  Project: Research project

• Finished

  Prot #1199-0324: Study of Pulmonary Rehabilitation In Nintedanib Treated Patients with IPF: Improvements in Activity, Exercise Endurance Time, and QoL

  Dematte D'Amico, J. E. & Bhorade, S. M.

  Boehringer Ingelheim Pharmaceuticals, Inc.

  2/28/19 → 2/28/22

  Project: Research project

• Wnt-beta-catenin cross interactions in alveolar macrophages and epithelial cells in persistence of SSc-ILD

  Dematte D'Amico, J. E., Gottardi, C., Hinchcliff, M. E., Lam, A. P., Berdnikovs, S., Budinger, G. S., Dematte D'Amico, J. E., Hinchcliff, M. E. & Misharin, A.

  National Heart, Lung, and Blood Institute

  12/22/17 → 11/30/22

  Project: Research project

  • Systemic Scleroderma 100%
  • Interstitial Lung Disease 83%
  • Macrophage 74%
  • lungs 51%
  • Lung 48%

• Prot #EMR200017-014: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Efficacy and Safety of Abituzuma in Subjects with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

  Dematte D'Amico, J. E.

  Quintiles, Inc., EMD Serono Research & Development Institute, Inc.

  9/12/16 → 9/12/19

  Project: Research project

• Prot #1199.214: A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease’(SSc-ILD)

  Dematte D'Amico, J. E.

  Boehringer Ingelheim Pharmaceuticals, Inc.

  2/11/16 → 11/30/21

  Project: Research project

• Prot #PSSc-001: An Open-Label, Randomized, Phase 2 Study of the Safety and Tolerability of Pirfenidone when Administered to Patients with Systemic Sclerosis−Related Interstitial Lung Disease; The LOTUSS Trial: An Open-Label, RandOmized, Phase 2 STUdy of t

  Dematte D'Amico, J. E.

  InterMune, Inc.

  9/5/13 → 9/5/16

  Project: Research project

• Prot# ACE114622: A Two Part Study to Investigate the Safety, Tolerability, Pharmacokinetics and Parmacodynamics of GSK2586881 in Patients with Acute Lung Injury

  Wunderink, R. G., Dematte D'Amico, J. E. & Weiss, C. H.

  GlaxoSmithKline LLC

  5/8/12 → 10/10/14

  Project: Research project

• Prot# AC-063B201: A Phase 2, Multi-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Inhaled Iloprost on Endurance Time During Cardiopulmonary Exercise Testing in Patients with Pulmonary Hypertension Secondary to Chroni

  Cuttica, M. J., Dematte D'Amico, J. E., Kalhan, R., Rosenberg, S. R. & Shah, S. J.

  Actelion Ltd.

  3/19/12 → 3/19/15

  Project: Research project

• PKD11791: A Randomized, Double-blind, Placebo-Controlled Trial to Assess the Pharmacokinetics, Pharmacodynamics and Safety of a Single Dose of SAR279356 in Patients Hospitalized in Intensive Care Unit and on Mechanical Ventilation

  Wunderink, R. G., Dematte D'Amico, J. E. & Prickett, M.

  Sanofi US Services Inc.

  10/27/11 → 10/27/14

  Project: Research project

• Prot#RIN-PH-403: A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated with Tyvaso (Treprostinil) Inhalation Solution

  Cuttica, M. J., Dematte D'Amico, J. E. & Shah, S. J.

  United Therapeutics Corporation

  9/29/11 → 2/28/15

  Project: Research project

• Prot#BSTE-0409: Rapid Evaluation of Acute Kidney Injury with NGAL in Acutely Ill Patients in the ICU (REAL-ICU)

  Wunderink, R. G., Dematte D'Amico, J. E. & Weiss, C. H.

  Alere San Diego, Inc.

  4/20/11 → 4/19/14

  Project: Research project

• Prot# PAB05: Estimation of the Incidence of Ventilator-Associated Pneumonia Caused by Pseudomonas aeruginosa (VAP-Pa)

  Wunderink, R. G., Dematte D'Amico, J. E. & Weiss, C. H.

  Clinical Financial Services, LLC, Sanofi Pasteur Limited

  3/21/11 → 3/21/14

  Project: Research project

• AGMT 02/10/11: CONFRONT PAH: CombinatiON up-FRON t Therapy for PAH-A Phase 4, Randomized, Multicenter Study of Inhaled Treprostinil in Treatment-naive Pulmonary Arterial Hypertension Patients Starting on Tadalafil

  Cuttica, M. J., Dematte D'Amico, J. E. & Shah, S. J.

  United Therapeutics Corporation

  2/10/11 → 2/10/17

  Project: Research project

• Prot# AC-063A402: A Phase IIIb, Multicenter, Open-Label Study of Patients with Pulmonary Arterial Hypertension Treated with Iloprost (Inhalation) Evaluating Safety and Inhalation Times When Converting from Power Disc-6 to Power Disc-15 With the I-Neb AAD

  Dematte D'Amico, J. E., Cuttica, M. J. & Shah, S. J.

  Paragon Biomedical, Inc., Actelion Ltd.

  5/14/09 → 5/14/12

  Project: Research project

• Prot# F1K-MC-EVDP: Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients with Septic Shock

  Wunderink, R. G. & Dematte D'Amico, J. E.

  Parexel, Eli Lilly and Company

  4/28/09 → 4/28/12

  Project: Research project

• Prot# CA-ALT-836-01-08: Efficacy and Safety Evaluation of ALT-836 in Patients with Sepsis and Acute Lung Injury/Acute Respiratory Distress Syndrome

  Wunderink, R. G., Cuttica, M. J., Dematte D'Amico, J. E., Jain, M. & Weiss, C. H.

  Altor BioScience Corporation

  4/20/09 → 4/20/12

  Project: Research project

• Prot# A8811020: A Phase 2 Randomized, Double-Blind, Double-Dummy Efficacy, Safety and Tolerability Study of IV Sulopenem with Switch to Oral PF-03709270 Compared to Ceftriaxone with Step Down to Amoxicillin/Clavulanate Potassium (Augmentin) in Subjects wi

  Wunderink, R. G. & Dematte D'Amico, J. E.

  ICON Clinical Research, LLC, Pfizer Inc.

  1/28/09 → 1/28/12

  Project: Research project

• Prot# CEFTONOS1002: Open-Label, Exploratory, Multiple-Dose Study of Ceftobiprole to Evaluate the Pharmacokinetics and Broncho Alveolar Penetration in Adults with Ventilator-Associated Pneumonia

  Wunderink, R. G., Dematte D'Amico, J. E., Jain, M. & Prickett, M.

  Janssen Research & Development, LLC

  11/19/08 → 11/30/10

  Project: Research project